lost its pricing power in many countries, as evidenced by reimbursement
authorities' willingness to delay or outright deny access to drugs whose costs
are deemed unacceptable. Now, the availability of a costly drug in the U.S.
that could be given to millions of people has sparked the strongest backlash
against drug pricing the industry has yet faced - in the last major market
where the government has not adopted any form of drug price controls, according
to the U.S. Department of Commerce.
Last year, in
"Facing Reality," Back to School argued biopharma
companies can no longer assume the market will support premium pricing, even
for drugs that deliver meaningful and measurable improvements over the standard
As the drumbeat for cost-based pricing grows louder, the 22nd Back to School essay says industry must experiment with new pricing models in which the cost of a given treatment is based on the patient-defined value of expected benefits, rather than the number of pills or injections dispensed.
The Index Nursery plans to disclose the misses as well as the hits of killer experiments run by the VC's incubator.
Covagen's largest investor said the company's takeout by J&J is likely one of the biggest this year for a venture-backed European biotech in both deal value and investor returns.
Firm seeks 'transformative' investments for new $410M fund. Plus: HealthQuest debuts; KalVista eyes DME; Kite; Regado; InterMune et al.
Dezima Pharma B.V. (Naarden, the Netherlands) said TA-8995 (DEZ-001) alone or in combination with statin therapy met the primary endpoint vs. placebo in the 364-patient Phase IIb TULIP trial to treat dyslipidemia. The primary endpoint was...
The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K.
The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier riches for the top labs but instead makes a difference for up-and-coming researchers.
GSK executive Perry Nisen has joined Sanford-Burnham as CEO and plans to apply his industry know-how to accelerate drug development at the institute.
The mechanisms by which dysfunctional glial cells contribute to ALS have remained poorly defined. Now, Harvard University researchers have identified a therapeutic target-prostaglandin D2 receptor subtype DP1-and shown that reducing its expression can prolong survival in a mouse model of ALS.
Treating cardiac hypertrophy with MST2 inhibitors; improving the outcome of HSC transplants with RET agonists; preventing allergic asthma with Helicobacter pylori ggt and vacA; and more...
An Sigirr-deficient mouse model of Campylobacter jejuni infection; a CAR-specific invariant NK T cell therapy; integrated analysis of cancer cells to prioritize the study of cancer drivers; and more...